Abatacept is useful in autoimmune cytopenia with immunopathologic manifestations caused by CTLA-4 defects

Blood. 2022 Jan 13;139(2):300-304. doi: 10.1182/blood.2021013496.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abatacept / therapeutic use*
  • Adolescent
  • Adult
  • Anemia, Hemolytic, Autoimmune / drug therapy*
  • Anemia, Hemolytic, Autoimmune / genetics
  • Autoimmune Diseases / drug therapy
  • Autoimmune Diseases / genetics
  • CTLA-4 Antigen / genetics*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Male
  • Thrombocytopenia / drug therapy*
  • Thrombocytopenia / genetics
  • Young Adult

Substances

  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Immune Checkpoint Inhibitors
  • Abatacept

Supplementary concepts

  • Evans Syndrome